|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 31/529 | |
| A61K 31/519 | |||
| A61K 31/5355 | |||
| A61K 31/56 | |||
| A61K 39/395 | |||
| A61K 45/06 | |||
| A61P 37/06 |
| (11) | Patento numeris | 3355891 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 16852514.5 |
| Europos patento paraiškos padavimo data | 2016-09-28 | |
| (97) | Europos patento paraiškos paskelbimo data | 2018-08-08 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2021-01-13 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2016/054231 |
| Data | 2016-09-28 |
| (87) | Numeris | WO 2017/058950 |
| Data | 2017-04-06 |
| (30) | Numeris | Data | Šalis |
| 201562233715 P | 2015-09-28 | US |
| (72) |
BETTS, Brian C., US
YU, Xuezhong, US
ANASETTI, Claudio, US
|
| (73) |
CTI Biopharma Corp.,
3101 Western Avenue 600, Seattle, Washington 98121,
US
|
| (54) | PACRITINIB FOR USE IN TREATING TRANSPLANT REJECTION |
| PACRITINIB FOR USE IN TREATING TRANSPLANT REJECTION |